Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Can multisource immediate release amodiaquine products qualify for BCS based biowaivers?
- In: Biopharmaceutics Classification System Posters
- At: Hyderabad (India) (2011)
- Type: Poster
- Poster code: BCS-P-01
- By: NAIR, Anita (Goethe University, Frankfurt Am Main, Germany)
- Co-author(s): Dressman B, Jennifer (Goethe University, Frankfurt Am Main, Germany)
Background information; Amodiaquine, frequently prescribed along with artesunate, is recommended for the treatment of uncomplicated falciparum malaria by the WHO. It is widely adopted for malarial treatment across sub-Saharan regions due to its high efficacy and tolerance. The biowaiver procedure based Biopharmaceutical Classification System (BCS).. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019